US30050B1017
US30050B1017
Evolent Health, Inc
Loading chart...
Valuation & History
Quarterly trend of key valuation metrics
| Metric | Current (TTM) TTM Baseline | Q2 '26 30.06.2026 | Q1 '26 31.03.2026 | Q4 '25 31.12.2025 |
|---|---|---|---|---|
Market & Enterprise Value | ||||
Market Cap | 456.76M EUR | 610.75M EUR | 256.45M EUR | 446.53M EUR |
Enterprise Value | 1.3B EUR | 1.47B EUR | 1.1B EUR | 1.28B EUR |
Valuation Multiples | ||||
Trailing P/E | -- | -- | -- | -- |
Forward P/E | 10x | -- | -- | -- |
Price to Sales | 0.22x | 0.29x | 0.14x | 0.32x |
Price to Book | 1.19x | 1.59x | 0.65x | 1.08x |
EV/Revenue | 0.62x | 0.7x | 0.58x | 0.92x |
EV/EBITDA | 21.34x | 21.8x | 14.94x | 21.09x |
Price to FCF (P/FCF) | 2.48x | 25.09x | 183.83x | 50.83x |
EV/FCF | 7.07x | 60.21x | 788.42x | 146.2x |
FCF Yield | 40.35% | 3.98% | 0.54% | 1.97% |